Although the rationale behind the negative impact of TGR0 on the efficacy of ICI is unclear, it could be hypothesized that the immune microenviroment of fast-growing tumor is unfavorable for the action of PD-1 axis inhibitors. The gene discussed is PDCD1; the disease is neoplasm.